Prediction and Characterization of Diffuse Large B-Cell Lymphoma Cell-of-Origin Subtypes Using Targeted Sequencing

References

• TL R , DCE, CJR, MLM, AhmedinJ, FCR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin.66(6), 443–459 (2016).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH , CampoE, PileriSAet al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood127(20), 2375–2390 (2016).
   PubMed Web of Science ®Google Scholar
• Alizadeh AA , EisenMB, DavisREet al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature403, 503–511 (2000).
   PubMed Web of Science ®Google Scholar
• Lenz G , WrightG, DaveSSet al. Stromal Gene Signatures in Large-B-Cell Lymphomas. N. Engl. J. Med.359(22), 2313–2323 (2008).
   PubMed Web of Science ®Google Scholar
• Scott DW , WrightGW, WilliamsPMet al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood123(8), 1214–1217 (2014).
   PubMed Web of Science ®Google Scholar
• Reddy A , ZhangJ, DavisNSet al. Genetic and functional drivers of diffuse large B-cell lymphoma. Cell171(2), 481–494 (2017).
   PubMed Web of Science ®Google Scholar
• Hans CP , WeisenburgerDD, GreinerTCet al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood103(1), 275–282 (2003).
   PubMed Web of Science ®Google Scholar
• Gribben RC , AndrewJames C, AndrewOet al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin. Cancer Res.19(24), 6686–6695 (2013).
   PubMed Web of Science ®Google Scholar
• Meyer PN , FuK, GreinerTCet al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol.29(2), 200–207 (2011).
   PubMed Web of Science ®Google Scholar
• Staiger AM , ZiepertM, HornHet al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J. Clin. Oncol.35(22), 2515–2526 (2017).
   PubMed Web of Science ®Google Scholar
• Morin RD , JohnsonNA, SeversonTMet al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet.42, 181–185 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenwald A , WrightG, ChanWCet al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med.346(25), 1937–1947 (2002).
   PubMed Web of Science ®Google Scholar
• Intlekofer AM , JoffeE, BatleviCLet al. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J.8(6), 60 (2018).
   PubMedGoogle Scholar
• Ngo VN , YoungRM, SchmitzRet al. Oncogenically active MYD88 mutations in human lymphoma. Nature470, 115–119 (2010).
   PubMed Web of Science ®Google Scholar
• Davis RE , NgoVN, LenzGet al. Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature463, 88–92 (2010).
   PubMed Web of Science ®Google Scholar
• Scherer F , KurtzDM, NewmanAMet al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med.8(364), 364ra155 (2016).
   PubMed Web of Science ®Google Scholar
• Chapuy B , StewartC, DunfordAJet al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med.24(5), 679–690 (2018).
   PubMed Web of Science ®Google Scholar
• Schmitz R , WrightGW, HuangDWet al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med.378(15), 1396–1407 (2018).
   PubMed Web of Science ®Google Scholar
• Vitolo U , TrnenyM, BeladaDet al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J. Clin. Oncol.35(31), 3529–3537 (2017).
   PubMed Web of Science ®Google Scholar
• Seymour JF , PfreundschuhM, TrnenyMet al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica99(8), 1343–1349 (2014).
   PubMed Web of Science ®Google Scholar
• He J , Abdel-WahabO, NahasMKet al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood127(24), 3004–3014 (2016).
   PubMed Web of Science ®Google Scholar
• Sun JX , HeY, SanfordEet al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput. Biol.14(2), e1005965 (2018).
   PubMed Web of Science ®Google Scholar
• Chalmers ZR , ConnellyCF, FabrizioDet al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med.9(1), 34 (2017).
   PubMed Web of Science ®Google Scholar
• Zehir A , BenayedR, ShahRHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10.000 patients. Nat. Med.23(6), 703–713 (2017).
   PubMed Web of Science ®Google Scholar
• Alexandrov LB , Nik-ZainalS, WedgeDCet al. Signatures of mutational processes in human cancer. Nature500(7463), 415–421 (2013).
   PubMed Web of Science ®Google Scholar
• Lenz G , WrightGW, EmreNCTet al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl Acad. Sci. USA105(36), 13520–13525 (2008).
   PubMed Web of Science ®Google Scholar
• Jardin F , JaisJ-P, MolinaT-Jet al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood116(7), 1092–1104 (2010).
   PubMed Web of Science ®Google Scholar
• McCord R , BolenCR, KoeppenHet al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv.3(4), 531–540 (2019).
   PubMed Web of Science ®Google Scholar
• Andorsky DJ , YamadaRE, SaidJ, PinkusGS, BettingDJ, TimmermanJM. Programmed death ligand 1 is expressed by non–Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res.17(13), 4232 (2011).
   PubMed Web of Science ®Google Scholar
• Chen BJ , ChapuyB, OuyangJet al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin.Cancer Res.19(13), 3462–3473 (2013).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , CiuleanuT-E, PluzanskiAet al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med.378(22), 2093–2104 (2018).
   PubMed Web of Science ®Google Scholar
• Ansell SM , MinnemaMC, JohnsonPet al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J. Clin. Oncol.37(6), 481–489 (2019).
   PubMed Web of Science ®Google Scholar
• Wilson WH , YoungRM, SchmitzRet al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med.21(8), 922–926 (2015).
   PubMed Web of Science ®Google Scholar
• Kotnis A , DuL, LiuC, PopovSW, Pan-HammarströmQ. Non-homologous end joining in class switch recombination: the beginning of the end. Philos. Trans. R. Soc. Lond. B. Biol. Sci.364(1517), 653–665 (2009).
   PubMed Web of Science ®Google Scholar
• Arthur SE , JiangA, GrandeBMet al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat.Commun.9(1), 4001 (2018).
   PubMedGoogle Scholar
• Pascual M , Mena-VarasM, RoblesEFet al. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas. Blood133(22), 2401–2412 (2019).
   PubMed Web of Science ®Google Scholar